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Genetic Advances Uncover Mechanisms of
Chemotherapy-induced Peripheral Neuropathy
KC Chua1 and DL Kroetz1
Chemotherapy-induced peripheral neuropathy (CIPN) is a
common dose-limiting toxicity experienced in 30–40% of
patients undergoing treatment with various chemotherapeutics,
including taxanes, vinca alkaloids, epothilones, proteasome
inhibitors, and thalidomide. Importantly, CIPN signiﬁcantly
affects a patient’s quality of life. Recent genetic association stud-
ies are enhancing our understanding of CIPN pathophysiology
and serve as a foundation for identiﬁcation of genetic bio-
markers to predict toxicity risk and for the development of nov-
el strategies for prevention and treatment.
CHARACTERISTICS OF CHEMOTHERAPY-INDUCED
PERIPHERAL NEUROPATHY
Chemotherapy-induced nerve damage is predominantly a sensory
neuropathy that manifests as numbness/tingling and burning
sensations in a “glove and stocking” distribution, in which the
longest axons and most distal nerves are ﬁrst affected.1 Debilitat-
ing chemotherapy-induced peripheral neuropathy (CIPN) symp-
toms that cause sensitivity to extreme temperatures and signiﬁcantly
interfere with daily activities, such as writing, dressing, or even
walking, can linger for up to 2 years and may never completely
reverse in severe cases.1,2 Clinical risk factors for developing
CIPN include pre-existing neuropathy (e.g., diabetic neuropathy),
prior treatment with neurotoxic agents, and high-exposure dosing
regimens; however, these factors alone do not account for the
interindividual variation in CIPN observed clinically. As the
number of cancer survivors continues to increase, the importance
of CIPN on long-term quality of life has gained recognition.
Despite efforts to identify therapeutic approaches to combat
CIPN, there are currently no clinical recommendations for pre-
vention and only a moderate recommendation for the use of
duloxetine in the treatment of CIPN.1 The development of clini-
cally effective therapies to prevent and/or treat CIPN is limited
by our current understanding of the pathophysiological mecha-
nisms behind this toxicity. It is still unclear what underlying
genes or genetic networks determine the risk of CIPN and how
they manifest the toxicity. Advances in genomic and stem cell tech-
nologies provide new approaches to address current gaps in our
knowledge of drug-induced peripheral neuropathy (Figure 1).
Below we discuss the application of genomics for discovering the
pathophysiological mechanisms governing CIPN and the potential
for a precision medicine-based approach in its prevention and/or
treatment.
GENETIC ASSOCIATION STUDIES PROVIDE CLUES TO THE
MOLECULAR MECHANISMS UNDERLYING
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
Advances in genomewide approaches allow the capture of novel
associations in an unbiased manner, interrogating both direct
and indirect genetic effects on CIPN. Although sample size limi-
tations preclude the identiﬁcation of speciﬁc genetic variants that
are strongly associated with CIPN, the power of genomewide
association studies (GWAS) are in the identiﬁcation of critical
genes important in the pathophysiology underlying this toxicity.
Although clinical presentation of CIPN is relatively consistent
among chemotherapies, recent genetic ﬁndings suggest that the
predisposition and development of neurotoxicity may involve
drug-speciﬁc genetic networks. Further studies are needed to
understand whether there may also be molecular mechanisms
underlying CIPN that are shared across drugs.
Novel genes found from GWAS on CIPN have alluded to the
importance of biological pathways in peripheral nerve damage
and repair (summarized in Supplementary Table S1 online). A
GWAS on oxaliplatin-induced neuropathy implicated genes
relating to nerve development and neuron extension (FOXC1,
ITGA1) and pain signaling neurotransmitters (TAC1).2 The ﬁrst
GWAS on paclitaxel-induced peripheral neuropathy identiﬁed
three novel genes important in neurite growth during develop-
ment (EPHA5, FZD3) and in regulation of actin in ﬁlopodia/
lamellipodia formation (FGD4).3 Importantly, EPHA5 and relat-
ed EPHA receptors were independently identiﬁed by multiple
laboratories as critical genes for paclitaxel-induced CIPN. A
recent GWAS of docetaxel-induced peripheral neuropathy
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identiﬁed a gene implicated in neurodegeneration (VAC14; Sup-
plementary Table S1 online); a gene related to cellular structure
(CEP72) was identiﬁed in a GWAS for vincristine-induced neu-
rotoxicity.2 The implication of genes with known functions in
nerve damage and repair is mirrored in the connection between
rare congenital peripheral neuropathies and more common drug-
induced neuropathies. In these cases, individuals with common
genetic variants in Charcot-Marie-Tooth disease genes responsi-
ble for neuron morphogenesis (ARHGEF10, FGD4) only devel-
op neuropathy symptoms when exposed to chemotherapeutics.2
Genetic association studies have also provided evidence that
the cellular response to cytotoxic agents is involved in the devel-
opment of CIPN. Genes related to apoptosis (ALOX12, CASP9)
and inﬂammation (CTLA4) have been implicated in bortezomib-
induced neuropathy.2 Genetic association data support the proposed
mechanism that platinum agent-induced neuronal damage is ini-
tiated by the accumulation of platinum adducts in the dorsal
root ganglion, a cluster of sensory nerve cell bodies that relays
signals from peripheral neurons to the spinal cord.4 Platinum-
induced neuropathy ensues as a result of inefﬁcient cellular
defenses to DNA damage/oxidative stress that inhibit proper
neuronal regeneration.2
A signiﬁcant challenge for all pharmacogenetic studies is ﬁnd-
ing appropriately sized and phenotyped populations for replica-
tion. As a result, the translation of the GWAS ﬁndings described
here for the prediction of CIPN in patients will require further
validation. Nonetheless, these ﬁndings have begun to distinguish
the different genetic networks that inﬂuence the development of
CIPN, providing a foundation to translate genetic associations
into effective therapeutic strategies for the prevention and/or
treatment of this dose-limiting toxicity.
FUNCTIONAL MODELS OF CHEMOTHERAPY-INDUCED
PERIPHERAL NEUROPATHY
The application of genomic technologies has highlighted the
genetic complexity underlying this drug-induced toxicity; robust
CIPN model systems are now needed to investigate how chemo-
therapeutics induce peripheral nerve degeneration and how
genetic variations affect such response to chemotherapy stress.
Rodent models have revealed key morphological changes in the
affected nerves that are now hallmarks of CIPN, including the
loss of intra-epidermal nerve ﬁber endings, preferential sensory
axonal degeneration, mitochondrial vacuolation, and varying
degrees of demyelination.2 Although animal models are necessary
for investigating potential neuroprotective treatments, they are
not particularly efﬁcient for multigene validation and network
characterization. Studies in cultured dorsal root ganglion neurons
and human neuroblastoma cell lines have suggested possible
molecular mechanisms that cause CIPN, including drug trans-
porters controlling neuronal drug exposure, ion channels
involved in thermal sensitivity/insensitivity, calcium signaling
responsible for maintaining mitochondrial function, mitochondrial
Figure 1 The precision medicine approach incorporates both genomewide association studies and functional models to understand the molecular mech-
anisms underlying chemotherapy-induced peripheral neuropathy (CIPN) with the goal of discovering novel strategies to prevent and treat this dose-limiting
toxicity. The identification of genetic biomarkers will enable screening for CIPN risk, thereby improving clinical decisions. In vitro models to study CIPN
have the potential to inform how patient susceptibility develops, identify novel therapeutic strategies for treatment and prevention, and test new chemical
entities for liability for this toxicity.
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DNA stability, and response to oxidative stress.2 It is still unclear,
however, which mechanisms are the primary cause for pathogene-
sis of CIPN and which are secondary cellular responses after
onset of peripheral degeneration.
The inability to readily obtain and examine human sensory
neurons that truly embody appropriate responses to chemothera-
py exposure limits our ability to deﬁne the molecular mechanisms
important in drug-induced sensory peripheral neuropathy. The
application of human-induced pluripotent stem cell (iPSC) tech-
nology holds the potential for rapid advances in understanding
CIPN on a molecular level, including the investigation of how
patient-speciﬁc genetic variation determines CIPN predisposition
and screening of potential neuroprotective targets in a high
throughput manner. The development of human iPSC-derived
sensory peripheral neurons is underway, and such models are
expected to mimic the target tissue, giving us better insight on
the functionality of identiﬁed genes on neuronal responses to
chemotherapy. Recent work in iPSC-derived central neurons has
demonstrated sensitivity to chemotherapy exposure that can be
modulated by genetic disruption of genes previously associated
with CIPN (e.g., TUBB2A and VAC14),2,5 setting a precedent
for how patient-speciﬁc genetic variations can be investigated.
The iPSC-derived sensory neurons can reveal genetic signatures
present only under chemotherapy exposure, further enhancing
our comprehension of how human peripheral neurons respond
after chemotherapy exposure and distinguishing which genetic
networks contribute to the primary mechanisms of CIPN. Fur-
thermore, these systems may enhance drug development efforts
by providing better prediction of the efﬁcacy of CIPN-targeted
therapies and the propensity for new therapeutic agents for
CIPN-like toxicities. With the development of appropriate in
vitro tools, we will be able to build our knowledge regarding the
molecular mechanisms of CIPN development and thereby
expand possible targets for its prevention and treatment.
PERSPECTIVES/FUTURE
GWAS have revealed the polygenic nature of CIPN and suggest
a critical role for peripheral nerve repair pathways in determining
sensitivity to chemotherapeutic agents. As genomic sequencing
technologies advance and become more affordable, and standard
neurotoxicity assessments become readily available, novel clinically
relevant genetic associations will be uncovered and currently
reported associations will be validated. There remains a need for
more in vitro tools to extend genetic ﬁndings into molecular
mechanisms that can be exploited for novel therapies against
CIPN. Human iPSC-derived sensory neurons hold great promise
for understanding the genes and pathways underlying the devel-
opment of drug-induced peripheral neuropathy, deﬁning the con-
tribution of genetic variation to the toxicity, and screening for
drug targets (Figure 1). Overall, we have only begun to address
the current gaps in our understanding of CIPN, but efforts to
uncover underlying genetic drivers and establish robust model
systems are critical steps for a precision medicine approach to
prevent and treat this complex drug-induced toxicity.
Additional Supporting Information may be found in the online version of
this article.
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